SCHEMBL30983363

SCHEMBL30983363

CC1(Oc2ncnc3c2nc(-c2cccc(OCCN4CCNCC4)c2Cl)n3Cc2ccccc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HTR1D P28221 4/20 0.40
▸ HTR1B P28222 4/20 0.40
▸ HTR1A P08908 3/20 0.40
▸ DRD2 P14416 3/20 0.36
▸ HTR6 P50406 3/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ LTA4H P09960 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983408 0.94 DRD2 (0.36) HTR1DHTR1BHTR1ADRD2HTR6
SCHEMBL30983490 0.92 HTR1D (0.43) HTR1DHTR1BHTR1ADRD2PIK3CD
SCHEMBL30983438 0.90 KIT (0.35) HTR1DHTR1BHTR1ADRD2HTR6
SCHEMBL30983530 0.89 PDE2A (0.38) HTR1DHTR1BHTR1ADRD2HTR6
SCHEMBL30983452 0.88 HTR1D (0.40) HTR1DHTR1BHTR1APIK3CDKDM4E
SCHEMBL30983953 0.87 HTR1A (0.38) HTR1DHTR1BHTR1ADRD2HTR6
SCHEMBL30983515 0.87 KIT (0.41) HTR1DHTR1BHTR1ADRD2HTR6
Hydrochloric Acid SCHEMBL31269160 0.87 HTR1A (0.37) HTR1DHTR1BHTR1ADRD2HTR6
SCHEMBL30983572 0.85 HTR6 (0.40) HTR1DHTR1BHTR1ADRD2HTR6
SCHEMBL30984032 0.85 PIK3CD (0.41) PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR1D 4542/4885HTR1B 4365/4885HTR1A 4588/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HTR1D 4542/4885HTR1B 4365/4885HTR1A 4588/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR1D 4542/4885HTR1B 4365/4885HTR1A 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback